江中药业(600750) - 2019 Q3 - 季度财报

Financial Performance - Operating income for the first nine months rose by 31.90% to CNY 1,703,612,827.72 year-on-year[18] - Net profit attributable to shareholders increased by 7.92% to CNY 381,635,134.81 compared to the same period last year[18] - Basic earnings per share increased by 8.96% to CNY 0.73[20] - Total revenue for the first three quarters of 2019 reached RMB 1,703,612,827.72, a 32% increase from RMB 1,291,549,708.18 in the same period of 2018[61] - Net profit for the first three quarters of 2019 was RMB 2,444,689,391.44, compared to RMB 2,301,480,318.23 in 2018, reflecting a growth of approximately 6.2%[60] - The net profit for Q3 2019 was CNY 133,499,477.02, an increase from CNY 125,289,147.95 in Q3 2018, representing a growth of approximately 1.0%[68] - Total profit amounts to 149,902,345.62 CNY, up from 111,233,772.74 CNY, indicating a growth of about 34.8%[76] Cash Flow - Cash flow from operating activities surged by 70.95% to CNY 641,681,356.55 year-on-year[18] - The net cash flow from operating activities for the period was 641.68 million RMB, an increase of 70.95% compared to the same period last year, mainly due to an increase in bank acceptance bill collections[34] - Cash inflow from investment activities totals 1,356,757,911.31 CNY, significantly higher than 43,504,082.70 CNY previously, marking a substantial increase[82] - Cash outflow from investment activities is 1,892,713,444.75 CNY, compared to 108,749,358.10 CNY in the previous period, indicating a significant rise in investment expenditures[82] - The net cash flow from investment activities is -535,955,533.44 CNY, worsening from -65,245,275.40 CNY previously, reflecting increased investment outflows[82] - Total cash inflow from operating activities reached CNY 1,340,504,541.37, up from CNY 1,161,869,000.26 year-over-year[84] - Cash outflow from operating activities decreased to CNY 741,136,316.21 from CNY 832,302,133.74, reflecting improved operational efficiency[84] Assets and Liabilities - Total assets increased by 18.03% to CNY 4,505,320,439.77 compared to the end of the previous year[18] - The company's current assets totaled CNY 2,841,185,125.50, up from CNY 2,293,747,071.49 in the previous year, indicating a growth of approximately 23.9%[46] - The total liabilities of the company were CNY 633,228,513.93, compared to CNY 563,530,666.77 in the previous year, reflecting an increase of about 12.3%[52] - The total equity attributable to shareholders of the parent company rose to CNY 3,516,156,638.57 from CNY 3,253,296,386.76, marking an increase of approximately 8.1%[52] - The total liabilities decreased to RMB 292,760,731.91 from RMB 363,524,950.67, a reduction of about 19.5%[58] - Total liabilities amounted to 363,524,950.67, with current liabilities at 253,725,292.30[103] Investments and Acquisitions - The company completed acquisitions of Sanghai Pharmaceutical and Jisheng Pharmaceutical, leading to an increase in the scope of consolidation[26] - The company's goodwill at the end of the period was 17.79 million RMB, resulting from the difference between the acquisition price of subsidiaries and the fair value of identifiable net assets at the acquisition date[34] - The company reported a significant increase in long-term equity investments, rising to RMB 631,566,583.29 from RMB 259,477,560.52, marking a growth of approximately 143%[58] - The company received CNY 480,939,927.52 from investment recoveries, significantly up from CNY 52,670,000.00 in the previous year[84] Research and Development - The company's revenue from operations increased significantly due to the expanded consolidation scope, with R&D expenses rising to 29.94 million RMB, a growth of 100.54% year-on-year[34] - Research and development expenses for the first three quarters of 2019 were RMB 29,937,720.60, significantly higher than RMB 14,928,837.48 in the same period of 2018, reflecting an increase of about 100%[61] - Research and development expenses for Q3 2019 amounted to CNY 9,840,382.47, which is a significant increase from CNY 6,266,437.49 in Q3 2018, marking a rise of about 57.5%[73] Regional Performance - Revenue from non-prescription drugs reached CNY 1,323,162,321.27, with a growth of 18.55% year-on-year[24] - Revenue from the East China region grew by 43.81% to CNY 479,689,577.93 compared to the previous year[27] Other Financial Metrics - The gross margin for the pharmaceutical industry segment was 67.30%, a decrease of 0.57 percentage points compared to the previous year[22] - The weighted average return on net assets decreased by 0.35 percentage points to 11.26%[20] - The company reported a significant increase in minority shareholders' equity, which reached 355.94 million RMB, up 35.58 million RMB from the previous year, primarily due to the recognition of minority interests from subsidiaries acquired during the period[34] - The company distributed dividends totaling CNY 147,000,000.00, an increase from CNY 135,000,000.00 in the previous year[86]